- Target disease: Filarial diseases
- Main partners (since project start): National Museum of Natural History Paris (MNHN), France; Northwick Park Institute for Medical Research, UK; University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology, Germany.
- Start date:
- Funding (since project start): Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders; United States Agency for International Development (USAID), USA.
Oxfendazole is currently under development for treatment of neurocysticercosis and trichuriasis. Taking advantage of pre-clinical work already available in the public domain, DNDi is exploring the possibility of repurposing oxfendazole as a macrofilaricidal treatment for filarial indications.
Last update: August 2018